,End-to-End Regulatory Strategy for SaMD
With over 15 years of global regulatory consulting experience, Freyr supports SaMD innovators in designing compliant strategies aligned with IEC 62304, ISO 13485, ISO 14971, and EU MDR/IVDR frameworks. Our approach ensures your software meets international standards for safety, efficacy, and performance.
From SaMD regulatory processes, regulatory strategy, gap analysis, and risk management to technical documentation and submission support, we offer end-to-end consultation to accelerate approvals and ensure seamless market readiness. Our approach reflects global best practices in regulatory consulting for SaMD, ensuring every development stage aligns with evolving digital health expectations.
Leveraging our integrated RIMS platform, Freya Fusion, we deliver scalable, compliant, and efficient solutions for FDA clearance, CE marking, and global Regulatory harmonization. With Freyr as your partner, achieving fast, compliant, and successful SaMD launches worldwide becomes simpler and smarter.
SaMD Regulatory Strategy & Pathway Consultation Services
Freyr offers comprehensive end-to-end SaMD regulatory services and consultation solutions designed to meet regional requirements and align with SaMD risk profiles. Our services include:
![]()
Initial Product Assessment
Functional review, intended use mapping, and market readiness analysis.
![]()
Risk Classification & Standards Mapping
Alignment with ISO 13485, IEC 62304, IEC 82304-1, and national frameworks.
![]()
Regulatory Pathway Identification
FDA 510(k), De Novo, PMA, EU CE marking, Japan PMDA, and global equivalents.
![]()
Technical Documentation Review
Gap analysis and submission readiness checks.
![]()
In-Country Representation
Local regulatory representative for seamless communication with health authorities.
These SaMD consulting services ensure correct classification, documentation accuracy, and market readiness across geographies.
AI/ML-Based SaMD Compliance
AI-enabled medical software requires an adaptive regulatory strategy, especially as SaMD regulations evolves to address algorithm transparency, validation, and continuous learning. Freyr helps clients navigate emerging frameworks like the EU AI Act and FDA’s AI/ML SaMD action plan, addressing validation, transparency, and continuous learning considerations. Our expertise ensures your AI-driven SaMD remains compliant through model iterations and post-market updates.
Region-Specific Regulatory Pathways
We provide region-specific pathways that align with global SaMD regulatory processes, ensuring clarity on evidence requirements, classifications, and submission activities.
![]()
U.S. FDA
- SaMD classification and compliance strategy
- 510(k), De Novo, and PMA submissions
![]()
Europe (EU MDR/IVDR)
- Qualification as Medical Device Software (MDSW)
- CE conformity assessment for Class I–III devices
![]()
Global Markets
- Regulatory strategy tailored for other geographies
- Market access planning and local representation support
Regulatory Intelligence & Horizon Scanning
Powered by Freya Fusion, Freyr’s integrated Regulatory Information Management (RIM) platform, we provide real-time intelligence and predictive insights to facilitate strategic decision-making for global SaMD regulation, enabling proactive adaptation to new and emerging requirements.
![Regulatory Intelligence (RI)]()
Periodic updates on evolving regional requirements (FDA guidance, MDCG notes, PMDA revisions, etc.)![A single partner for everything]()
Horizon scanning for Regulatory trends affecting AI/ML-based SaMDs![submission accuracy- ensuring]()
Competitor pathway mapping and benchmarking
Periodic updates on evolving regional requirements (FDA guidance, MDCG notes, PMDA revisions, etc.)
Horizon scanning for Regulatory trends affecting AI/ML-based SaMDs
Competitor pathway mapping and benchmarkingFreyr’s Regulatory roadmap outlines step-by-step actions across pre-submission, documentation,
submission, and post-approval stages-enabling faster decision-making and budget forecasting.
Roadmap Development for SaMD & Digital Health Applications
Our structured roadmap ensures your SaMD regulatory processes are efficient, predictable, and globally aligned.
Book a meeting with our experts today
- Schedule a call today
Why Partner with Freyr?
- Proven expertise with 150+ SaMD approvals across 120+ markets, including high-risk and AI-based products.
- Fifteen years of experience crafting global, region-specific strategies aligned with FDA, MDR, and IMDRF standards.
- Regulatory intelligence powered by Freya Fusion for real-time insights and accelerated submissions.
- Integrated end-to-end support from risk classification to post-approval lifecycle management.
- Trusted partner to leading MedTech and digital health innovators for compliant, scalable market access.
Frequently Asked Questions
01. Why is a regulatory strategy essential for Software as a Medical Device (SaMD)?
A defined regulatory strategy ensures that your SaMD meets the right classification, evidence, and compliance standards for each target market. It minimizes approval delays, aligns development with global frameworks like FDA, EU MDR, and IMDRF, and enables faster, more predictable market access through well-defined SaMD regulatory processes.
02. How does SaMD risk classification influence regulatory pathways?
Risk classification determines the depth of clinical evidence, documentation, and regulatory scrutiny required. For example, FDA’s risk-based framework and EU MDR’s rules for Medical Device Software (MDSW) define the applicable pathway, whether 510(k), De Novo, PMA, or CE marking, based on intended use, functionality, and patient impact.
03. What are the key elements of an effective SaMD regulatory strategy?
An effective strategy integrates product qualification, global standards mapping, technical documentation, and a proactive submission roadmap. It should also include risk management, cybersecurity planning, and early engagement with regulators to ensure alignment with evolving digital health and AI/ML-based SaMD requirements.
04. How do AI and machine learning affect SaMD regulatory strategies?
AI-driven SaMD requires special attention to data quality, model transparency, and algorithm change management. With the EU AI Act and FDA’s AI/ML framework shaping oversight, manufacturers must ensure robust validation, performance monitoring, and traceability to maintain compliance throughout the product’s lifecycle.
05. What role does regulatory intelligence play in SaMD compliance?
Regulatory intelligence enables continuous awareness of evolving global requirements, guidance updates, and competitor activities. Platforms like Freya Fusion support real-time monitoring, horizon scanning, and predictive insights, helping manufacturers adjust documentation, evidence, and strategy before policy changes affect approval timelines.
06. How can a regulatory roadmap improve SaMD launch efficiency?
A regulatory roadmap aligns product development, documentation, and submissions with regional SaMD regulation. By defining pre-submission, technical, and post-approval milestones, it prevents rework, supports parallel filings, and ensures each step, from design to vigilance, is strategically optimized for faster market readiness and sustained compliance.
07. Why is Freyr considered a preferred partner for SaMD regulatory strategy and consultation?
Freyr combines 15+ years of global regulatory consulting experience with deep domain knowledge in SaMD and digital health. Our team provides tailored strategies aligned with FDA, EU MDR, and IMDRF frameworks, supported by Freya Fusion’s regulatory intelligence platform, enabling faster approvals, reduced compliance risks, and optimized global market access.
